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Abstract: In this study, gellan gum (GG), a natural polysaccharide, was used to fabricate spherical
porous beads suitable as sustained drug delivery systems for oral administration. GG was cross-linked
with calcium ions to prepare polymeric beads. Rheological studies and preliminary experiments of
beads preparation allowed to identify the GG and the CaCl2 concentrations suitable for obtaining
stable and spherical particles. GG beads were formed, through ionotropic gelation technique, with
and without the presence of the synthetic clay laponite. The resultant beads were analyzed for
dimensions (before and after freeze-drying), morphological aspects and ability to swell in different
media miming biological fluids, namely SGF (Simulated Gastric Fluid, HCl 0.1 M) and SIF (Simulated
Intestinal Fluid, phosphate buffer, 0.044 M, pH 7.4). The swelling degree was lower in SGF than in
SIF and further reduced in the presence of laponite. The GG and GG-layered silicate composite beads
were loaded with two model drugs having different molecular weight, namely theophylline and
cyanocobalamin (vitamin B12) and subjected to in-vitro release studies in SGF and SIF. The presence
of laponite in the bead formulation increased the drug entrapment efficiency and slowed-down the
release kinetics of both drugs in the gastric environment. A moving-boundary swelling model with
“diffuse” glassy-rubbery interface was proposed in order to describe the swelling behavior of porous
freeze-dried beads. Consistently with the swelling model adopted, two moving-boundary drug
release models were developed to interpret release data from highly porous beads of different drugs:
drug molecules, e.g., theophylline, that exhibit a typical Fickian behavior of release curves and drugs,
such as vitamin B12, whose release curves are affected by the physical/chemical interaction of the
drug with the polymer/clay complex. Theoretical results support the experimental observations, thus
confirming that laponite may be an effective additive for fabricating sustained drug delivery systems.
Keywords: beads; gellan gum; ionotropic gelation; laponite; modeling study; swelling; gastrointestinal
drug release; polymer/clay composite
1. Introduction
Orally administered dosage forms are the most convenient formulations due to the easiness of
employment, pre-determined and measured doses and overall non-invasive nature of administration,
which increase the patient compliance. The successful oral formulation should deliver the required
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therapeutic dose to the specific site of action during the treatment period. However, the delivery
of a drug by a simple conventional dosage form normally results in the immediate release of the
active pharmaceutic ingredient and their use usually requires a high frequency of administration
and uncontrolled absorption. These considerations have guided researchers to focus their efforts on
improving oral delivery systems with the development of formulations providing more predictable
release rates as well as an increased bioavailability. Sustained release formulations are extensively
investigated in order to reduce the dosing frequency, thus resulting in increased patience compliance.
In the last decades, many biomaterials have been proposed as interesting materials in the design
of modified oral drug delivery systems in order to accomplish therapeutic or convenience purposes
not offered by conventional dosage forms.
Synthetic and natural polymers have been proposed for the development of oral extended-release
dosage forms. However, naturally derived polymers offer many advantages over synthetic polymers
related to their biocompatibility, biodegradability, non-toxicity and reasonable costs.
In particular, hydrophilic polymers, such as polysaccharides, are widely used as natural materials
in sustained oral dosage forms and the interest in the application of these polymers for prolonging drug
release has increased over the last decades [1]. The interest toward these polymers is related to their
swelling and filmogen [2] capabilities as well as their pH-sensitive [3,4] or floating capability [5–8].
Natural gums, such as gellan gum (GG), an anionic, high molecular weight polysaccharide, has
gained significant interest in the pharmaceutical field [9]. It consists of tetra-saccharide repeating units:
α-l-rhamnose, β-d-glucuronic acid and β-d-glucose in the molar ratio 1:1:2.
GG has proven to be a versatile material in the formulation of polymeric hydrogels, including
beads systems, due to its temperature sensitivity and ability to gel under mild conditions. In fact,
it forms stable hydrogel networks in the presence of cationic cross-linkers [10,11], so that ionotropic
gelation method can be employed for the synthesis of polymeric networks using divalent cations as
cross-linking agents [12–14]. The contact of the polymer with cations results in the instantaneous
formation of a gel matrix containing uniformly dispersed material throughout the crosslinked gellan
gum matrix.
Polymeric beads are widely used for oral sustained release; after beads are ingested, the drug
will slowly diffuse out from the polymer matrix, resulting in a prolonged release of the active agent.
Nevertheless, some drawbacks, related to the higher porosity of the matrix or poor mechanical resistance
of the polymeric network, could lead to a rapid and massive release in acidic dissolution medium [15].
Only a few polymers can be used in their pure form for the formulation of oral sustained release beads
and therefore their combination with other biocompatible materials has been investigated in order to
overcome these drawbacks. Clay minerals are one of the fillers that can be used, in combination with
many biopolymers, to improve their drug delivery properties [16–19]. The ultimate goal is to bring
together in the same material the best properties of the natural polymer and clay since each component
plays a key role in improving the properties of the nanocomposite hydrogels.
In this scenario, clay hydrogel beads have been widely investigated in oral drug delivery
applications, showing that mineral clays can be successfully used as functional additives in the
development of bead-modified systems [20].
The most commonly used clay minerals belong to the smectite family. Among the smectite
family, laponite Na0.7[(Si8Mg5.5Li0.3)O20(OH)4]0.7 is a synthetic clay composed of a layered structure
(30–25 nm diameter, 1 nm thickness) that has been used to synthesize a wide range of nano-composite
hydrogels [21–23]. Specifically, laponite (LAPO) nanoparticles can be uniformly dispersed within
the polymeric matrix where they self-arrange and act as both filler and cross-linker during gel
formation [24,25].
This study aims to verify the possibility of using laponite as an additive clay mineral to design
new composite gellan gum beads with highly specific characteristics, such as appropriate swelling
properties and release kinetics.
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Rheological studies and preliminary experiments of bead preparation allowed selecting the
gellan gum and crosslinker (CaCl2) concentrations suitable for obtaining stable and spherical particles.
Under optimized experimental conditions, laponite was uniformly dispersed in the polymeric solution
allowing the formation of nano-composite GG beads with reduced mesh size. In order to investigate
how the morphology, swelling and the release properties of the nano-composite hydrogels were affected
by the laponite, beads were loaded with two model drugs having different molecular weights and
release studies were performed in simulated gastric fluid (SGF) and in simulated intestinal one (SIF).
Mathematical models for swelling and drug release from these highly porous beads were proposed.
Reliable values of drug diffusion coefficients in different release media were obtained.
2. Materials and Methods
2.1. Chemicals
Theophylline, vitamin B12, methanol, acetic acid, hydrochloric acid and low acyl gellan gum
(GelzanTM) were purchased from Sigma Aldrich Company (Darmstadt, Germany), and calcium
chloride hydrate, potassium dihydrogen phosphate and sodium hydroxide from Carlo Erba Reagents
S.r.l (Milan, Italy). We used bidistilled water from Carlo Erba Reagents S.r.l. for the HPLC analysis.
For sample preparation and all the other analyses, we used demineralized water produced with a
Pharma20 equipment, Culligan Italiana S.p.A (Bologna, Italy). Laponite XLG was a gift of Rockwood
Additives Ltd. (Moosburg, Germany).
2.2. Rheological Measurements
Rheological experiments were performed with a Haake RheoStress 300 Rotational Rheometer
(Dreieich, Germany) equipped with a Haake DC10 thermostat. Oscillatory experiments were performed
at 25.0 ± 0.2 ◦C in the range 0.01–10 Hz on the hydrogels obtained from 1.0, 1.5 and 2.0% w/w GG
solutions. Enough quantity of each sample was carefully poured to completely cover the 6 cm
cone-plate geometry (angle of 1◦). For each sample, the linear viscoelastic range was evaluated: a 1%
maximum deformation was used.
2.3. Beads Preparation
Gellan gum (0.11, 0.165 or 0.22 g) was added to 11 mL of double distilled water and maintained
under stirring for 5 h at 80 ◦C until a homogeneous solution was produced. This solution was cooled
and kept at 40 ◦C. Then, 10 mL of this solution were carefully loaded into a syringe with a 21G needle,
ensuring no air bubbles were present, and added to a solution of calcium chloride (50 mL, 0.3% and
0.6% w/w) drop wise. The beads were left cross-linking for 10 min (curing time), then filtered and
washed four times with 10 mL of deionized water and freeze-dried. The curing time was optimized
to have maximum entrapment efficiency of the model molecules used. In fact, while longer curing
times increase the degree of crosslinking of the polymer, they also promote the effusion of the loaded
molecule out of the beads, thus reducing the final drug loading.
Beads including laponite were produced starting from a solution (11 mL) of GG (1.5% w/w) and
laponite (1.0% w/w) added drop wise to the solution of CaCl2 (0.3% w/w), thus following the same
procedure adopted for beads without laponite.
The diameter of fresh and freeze-dried beads was measured with a caliper along two orthogonal
directions, taking the average of the measurements as the mean diameter of the beads, whereas the
ratio between the two measurements was taken as the aspect ratio of the beads.
2.4. Determination of Swelling Degree
In order to quantify the swelling degree of the beads, 10 freeze-dried beads were weighed and
placed into a tulle net and submerged into 25 mL of simulated gastric fluid (SGF, HCl 0.1 M) or
simulated intestinal fluid (SIF, phosphate buffer 0.044 M, pH 7.4), maintained at 37.0 ± 0.5 ◦C. After
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5 min, the beads were removed, lightly blotted on paper to remove the excess liquid and weighed.
The beads were then submerged back into the medium and the process was repeated at established
time intervals up to 24 h. The experiments were carried out in triplicate with each value representing
the mean ± SD.
The swelling degree S was calculated using the following equation:
S =
weight o f swollen beads − weight o f dry beads
weight o f dry beads
. (1)
2.5. Preparation of Drug Loaded Beads
Gellan gum (0.165 g) was dissolved in 9 mL of distilled water using the method described in
Section 2.3. Theophylline or vitamin B12 (0.0146 g) were solubilized in 2 mL of water and added to
the cooled gellan gum solution, to make a final volume of 11 mL and a concentration of 1.5% w/w
of GG. The solution was stirred at 100 rpm for 10 min to ensure the drug homogeneously dispersed.
The beads were then formed using the method described in Section 2.3. Drug loaded beads including
laponite were prepared from a starting solution (9 mL) of gellan gum (0.165 g) and laponite (0.11 g)
and then following the same procedure adopted for drug loaded beads without laponite.
2.6. Drug Entrapment Efficiency
In order to determine the quantity of drug loaded into the beads, 15 mg of freeze-dried beads were
stirred vigorously in SIF for 1 h, to destroy the beads and extract the drug. The solution was filtered
and analyzed by HPLC. The apparatus consisted of a Perkin Elmer Series 200 LC pump, equipped with
a 235 Diode Array Detector and a Total-Chrom data processor (Perkin Elmer, Waltham, MA, USA).
HPLC analyses were carried out using a Merck Hibar LiChrocart (250–4.5 µm) RP-18 column under
isocratic conditions (0.7 mL/min) using a mobile phase constituted by methanol and acetic acid (0.1 M)
mixture in a proportion of 40:60 (v:v). Theophylline was monitored at λ = 280 nm and vitamin B12 at
λ = 360 nm. Under these conditions, the retention time of theophylline was about 6 min, while that of
vitamin B12 was about 4 min.
The drug entrapment efficiency was calculated using the following equation:
Drug entrapment e f f iciency (%) =
actual drug content o f beads
theoretical drug content o f beads
× 100. (2)
All experiments were carried out in triplicate and each value reported representing the mean, ± SD.
2.7. In Vitro Release Studies
Release studies from drug loaded beads with different formulations were performed separately in
SGF (HCl 0.1 M) and in SIF (phosphate buffer, pH 7.4) and sequentially in SGF and SIF to simulate the
drug release in the entire gastrointestinal tract. A total of 15 mg of drug loaded beads were added
to a known volume Vres of SIF or SGF, warmed to 37 ◦C in a water bath and stirred continuously at
200 rpm. At defined times, from 1 to 240 min, 1 mL of solution was withdrawn and replaced with
1 mL of fresh solution. Different volumes Vres = 50, 75, 100, 150, 175 mL were considered in order to
investigate the influence of the release volume Vres on release curves. See Section 4.5.1 for a discussion
on the role of Vres.
For gastrointestinal in-vitro release experiments, 15 mg of drug-loaded beads were added to
100 mL of SGF, warmed to 37 ◦C in a water bath and stirred continuously at 200 rpm. At defined
times, from 1 to 120 min, 1 mL of solution was withdrawn and replaced with 1 mL of fresh SGF. After
120 min, the beads were drained to remove excess acid and transferred into 50 mL of SIF. Every 15 min,
1 mL of solution was withdrawn and replaced with the same volume of SIF until 240 min and then
again after 24 h. By considering that, after the first 120 min, the beads had released from 60% to 95% of
the initially loaded drug, depending on the bead formulation, we chose to carry out the subsequent
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release in SIF in a smaller release volume (half of that in SGF) to maintain the drug concentration in
the release volume high enough to allow the subsequent HPLC analysis. Drug concentrations were
determined by HPLC analysis as reported in the previous section.
After 24 h, the beads were collected from the media and destroyed to extract and quantify the
drug still embedded into the beads. The release data were reported as drug concentration Cres(twi)
[mg/mL] at withdrawal times twi [min] and as fraction of drug released up to time twi with respect to
the total amount of drug loaded in the beads. The experiments were carried out in triplicate with each
value reported representing the mean ± SD.
2.8. Statistics
Statistical tests were performed to evaluate the effect of laponite on gastrointestinal release rates
of the two model molecules. Statistical analysis was performed with GraphPad Prism™ (Version 4.00)
software (GraphPad Software, Inc., San Diego, CA, USA). The Student’s t-test was applied to determine
the statistical significance between two different experimental conditions. The values of p < 0.05 were
considered significant.
3. Mathematical Modeling of Swelling and Drug release of Highly Porous Beads
3.1. Swelling Modeling
We adopted a radial one-dimensional model of swelling of spherical dry beads. A classical
approach to swelling of glassy polymers requires the solution of a moving boundary model describing
the solvent transport in the swollen gel and the time evolution of two fronts [26–28], the erosion front
(rubbery-solvent interface at r = S(t)) and the swelling front (glassy-rubbery interface at r = R(t)),
as shown in Figure 1.
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Figure 1. Schematic representation of moving fronts and solvent concentration profiles in a swelling
process of a r s erical bead. The two cases of a non-porous and a highly porous particle
(blue dotted line) are shown.
The solvent balance equation, writ en in terms of the solvent volumetric fraction ϕ(r,t) reads
∂ϕ
∂t
=
1
r2
∂
∂r
(
r2Ds(ϕ)
∂ϕ
∂r
− r2vsr(ϕ)ϕ
)
=
1
r2
∂
∂r
(
r2Ds(ϕ)(1−ϕ)∂ϕ∂r
)
, R(t) < r < S(t), (3)
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where vrs(ϕ) is the swelling velocity vrs(ϕ) = Ds(ϕ)∂ϕ/∂r and Ds(ϕ) is the solvent diffusion coefficient,
that can be assumed constant or a function of the solvent volume fraction ϕ.
Equation (3) must be solved with the boundary conditions,
[ϕ]r=S(t) = ϕeq, [ϕ]r=R(t) = ϕG f or R(t) > 0,
[
∂ϕ
∂r
]
r=0
= 0 f or R(t) = 0, (4)
and initial conditions ϕ(r,0) = ϕ0 for 0 ≤ r ≤ R0, where R0 is the initial radius of the dry particle, ϕeq is
the volume fraction at equilibrium and ϕG is the threshold volume fraction to initiate swelling.
If we assume that the glassy phase for r < R(t) is totally impermeable to the solvent (the solvent
diffusivity is zero in the glassy phase) the two fronts, the glassy-rubbery at r = R(t) and the
rubbery-solvent at r = S(t), evolve according to the Stefan boundary conditions,
(ϕG −ϕ0)dRdt = −Ds(ϕG)(1−ϕG)
[
∂ϕ
∂r
]
r=R(t)
, R(0) = R0, (5)
dS
dt
= Ds
(
ϕeq
)[∂ϕ
∂r
]
r=S(t)
, S(0) = R0. (6)
This model fits well with the case of a spherical initially non-porous particle for which the sharp
glassy-rubbery interface progressively moves towards the center of the particle and spherical glassy
inner core that progressively disappears. However, in the case of a porous particle, like the beads
under investigation, we can imagine that the solvent can penetrate and diffuse inside the glassy core
through the pore network and that the gelling transition occurs simultaneously both on the inside
and on the external surface of the bead. Therefore, it is not possible to identify a net glassy-rubbery
interface, but rather a “diffuse” interface as depicted in Figure 1. This phenomenon for porous-particles
has been modeled by assuming a non-zero solvent diffusivity in the glassy phase, thus introducing a
solvent concentration dependent diffusion coefficient as follows
Ds(ϕ) = D
sg
s f (ϕ), f (ϕ) =

1 f or ϕ ≥ ϕG
exp
{
−β ϕ−ϕG
ϕ0 −ϕG
}
f or ϕ < ϕG
, (7)
where Dssg is the solvent diffusivity in the swollen gel, assumed constant for ϕ > ϕG, and β is a
parameter controlling the decay of the diffusivity in the glassy core. The larger the porosity, the smaller
β, the greater the ability of the solvent to penetrate in the glassy core.
The solvent transport equation and boundary conditions in highly porous particles read as
∂ϕ
∂t
=
1
r2
∂
∂r
(
r2Ds(ϕ)(1−ϕ)∂ϕ∂r
)
, 0 < r < S(t),ϕ(0 ≤ r ≤ R0, t = 0) = ϕ0, (8)
[ϕ]r=S(t) = ϕeq,
[
∂ϕ
∂r
]
r=0
= 0, (9)
that are the same as Equations (3) and (4) with the basic difference that ϕ(r,t) is now defined in the entire
domain 0 ≤ r ≤ S(t) because the glassy-rubbery sharp interface R(t) has been removed and solvent
diffusion is allowed in the glassy region with diffusion coefficient given by Equation (7). The only
moving boundary is the gel-solvent interface at r = S(t), evolving in time according to Equation (6).
The “diffuse” interface swelling model introduces the only extra parameter β controlled by the bead
porosity. Figure 2A,B shows the spatial behavior of the normalized solvent volume fraction ϕ(r,t)/ϕeq,
for increasing times, as obtained from the numerical solution of the swelling model Equations (6)–(9),
for two different values of β, namely β = 2 (Figure 2A) and β = 8 (Figure 2B).
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Solvent concentration profiles for β = 8 show a very rapid decay of ϕ for ϕ < ϕG, thus exhibiting
a very sharp interface, typical of a non-porous particle. On the contrary, for β = 2 (porous particle)
concentration profiles exhibit a smoother behavior for ϕ < ϕG because of solvent penetration in the
glassy region.
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times during the swelling process. Dashed line indicates the value of ϕ /ϕeq, Black boxes highlight the
thickness of the diffuse glassy-rubbery interface. (A) β= 2, porous particle; (B) β= 8, non-porous particle.
The estimate of model parameters Dssg, β and ϕeq can be obtained by comparing model predictions
with experimental data for the temporal evolution and asymptotic value of the swelling degree S(t)
S(t) =
weight o f absorbed solvent
weight o f dry particle
=
ρs
∫ S(t)
0 ϕ 4pir
2dr
ρb (4/3) piR30
(10)
where ρs and ρb are the solvent and the freeze-dried bead densities, respectively.
The estimate of model parameters is fully addressed in Section 4.3 in connection with the analysis
of swelling data in both release media SGF and SIF.
3.2. Drug Release Modeling of No-Interacting Drugs
If we assume no physical/chemical interaction between the drug and the polymer or the
clay-polymer complex, the transport model for the drug concentratio cd(r,t), initially loaded in
the glassy core, reads as
∂cd
∂t
=
1
r2
∂
∂r
(
r2Dd(ϕ)
∂cd
∂r
− r2vsr(ϕ)cd
)
, 0 < r < S(t), cd(0 ≤ r ≤ R0, t = 0) = c0d, (11)
[cd]r=S(t) = Cres(t),
[
∂cd
∂r
]
r=0
= 0, (12)
where vrs(ϕ) is the point wise swelling velocity and Dd(ϕ) = Ddsg(ϕ)f(ϕ) is the drug diffusivity, modeled
exactly as the solvent diffusivity Ds(ϕ). Indeed, Ddsg is the drug diffusion coefficient in the swollen gel,
assumed constant for ϕ > ϕG, and f(ϕ) is the same function adopted to describe solvent penetration in
the glassy core, Equation (7). Consistently with the solvent penetration model adopted, drug diffusion
is allowed in the glassy core through the pore network, and the parameter β controlling diffusivity
decay in the glassy core is assumed the same for the solvent and the drug.
The concentration Cres(t), entering the boundary condition at the rubbery-solvent interface,
represents the drug concentration in the reservoir in which the beads are immersed for release,
with volume Vres, assumed perfectly mixed. Cres(t) evolves in time according to the macroscopic
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balance equation accounting for drug release from swelling beads and withdrawals, modeled as an
instantaneous depletion of drug concentration in the reservoir
Vres
dCres
dt
= Nbeads
−Dsgd [∂cd∂r
]
r=S(t)
4piS2(t)
−∑Ntwi=1 VwCres(t) δ(t− tiw), (13)
where Nbeads is the total number of swelling/releasing beads, Vw is the withdrawal volume, twi is the
time of the i-th withdrawal and NWt is the number of withdrawals from time zero to current time
t. The simplifying assumption of perfect sink condition is therefore replaced by the more accurate
expression Equation (13) for Cres(t) that, in the limit for Vres /Vbeads→∞, permits to recover the perfect
sink condition Cres(t) = 0. Equations (11)–(13) for drug transport must be solved together with Equations
(6)–(9) for solvent diffusion.
Figure 3A,B shows the spatial behavior of the normalized drug concentration (cd−Cres)/(cd0−Cres)
for increasing times as obtained by choosing β = 2 (porous particle) and β = 8 (non-porous particle) for
both Ds(ϕ) and Dd(ϕ). We observe that, for β = 2 (porous particle), the drug can smoothly diffuse out
of the glassy core through the pore network while, for β = 8 (non-porous particle), drug concentration
profiles exhibit a jump at the sharp glassy-rubber interface.
The estimate of the only model parameter Ddsg entering the drug release model is obtained
by direct comparison of model predictions for Cres(t) with experimental data for withdrawal drug
concentrations Cwi = Cres(twi) or by direct comparison of model predictions with experimental data of
the integral release curve
Mt
M∞
=
VresCres(t) +
∑Ntw
i=1 VwCres
(
tiw
)
VresCres(∞) + ∑Nwi=1 VwCres(tiw) , (14)
where Cres(∞) is the asymptotic concentration in the reservoir and NW is the total number of withdrawals
made during the entire release experiment.
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Figure 3. Normalized drug concentration (cd−Cres)/(cd0−Cres) vs. dimensionless radius r/R0 for
increasing times as obtained by adopting β = 2 ((A), highly porous particle) and β = 8 ((B), non-porous
particle) for particle swelling and drug transport. Black boxes highlight the thickness of the diffuse
glassy-rubbery interface.
3.3. Drug Release Modeling of Interacting Drugs
If we assume a physical/chemical interaction between the drug and the clay-polymer complex we
need to introduce a two-phase model, analogous to that adopted by Singh et al. (1994) [29] and by
Paolicelli et al. (2017) [30] modeling drug release from hydrogels via a diffusion transport equation
coupled with a sorption/desorption mechanism. The “two-phases” model adopted in the present
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work introduces a fraction ε of drug molecules initially bounded to the clay-polymer complex by a
physical bound and a “desorption” mechanism, occurring during solvent penetration, modeled as a
linear transfer rate from the adsorbed “bounded” phase to the desorbed “free” (or gel-solvent) phase
where the drug is free to diffuse with diffusion coefficient Dd(ϕ), the same adopted in Section 3.2 for
non-interacting drugs.
Let us then indicate with cb and cd the drug concentrations in the bounded and free (gel-solvent)
phases, respectively. Drug concentration cb(r,t) evolves in space and time according to the transport
equation for the clay-polymer complex during the swelling process
∂cb
∂t
=
1
r2
∂
∂r
(
−r2vsrcb
)
− kbg(ϕ)cb, 0 < r < S(t), cb(r , t = 0) = c0d,
[
∂cb
∂r
]
r=0
= 0, (15)
but including a linear transfer rate from the bounded to the free phase −rb→g = kbg(ϕ) cb, induced
by solvent penetration and modeled, according to the solvent diffusion model Equation (7),
as kbg(ϕ) = kbgsgf(ϕ) where kbgsg [1/s] is the transfer rate coefficient in the swollen gel, assumed
constant for ϕ > ϕG. Correspondingly, the transport equation for drug molecules in the free (gel) phase
cd(r,t) reads as
∂cd
∂t
=
1
r2
∂
∂r
(
r2Dd(ϕ)
∂cd
∂r
− r2vsrcd
)
+ kbg(ϕ)cb, 0 < r < S(t),
cd(r, t = 0) = (1− )c0d,
(16)
to be solved with the same boundary conditions Equation (12) adopted for the no-interaction model
and with Equation (13) for the time evolution of the drug concentration in the reservoir Cres(t).
The inverse of the transfer rate coefficient 1/kbgsg represents the characteristic time for the
irreversible transfer of a drug molecule from the bounded to the free (gel) phase. This characteristic
time tbg = 1/kbgsg can be compared to the characteristic drug diffusion time tD = R02/Ddsg by introducing
the Thiele modulus Φ2 = tD/tbg = kbgsg R02/Ddsg to identify the rate-controlling step.
The estimate of transport parameters, namely Ddsg, and kbgsg and is obtained by direct comparison
of model predictions with experimental data for withdrawal drug concentrations Cres(twi) and for the
integral release curves Mt/M∞.
3.4. Numerical Issues
PDE equations and boundary conditions describing the one-dimensional swelling dynamics and
drug release were numerically solved using finite elements method (FEM) in Comsol Multiphysics 3.5.
The convection–diffusion package was coupled with ALE (Arbitrary Lagrangian Eulerian) moving
mesh. Free displacement induced by boundary velocity conditions was set. Lagrangian quadratic
elements were chosen. The linear solver adopted was UMFPACK, with relative tolerance 10−4 and
absolute tolerance 10−7. The number of finite elements is 104 with a non-uniform mesh. Smaller
elements were located close to the boundary r = S(t) in order to accurately compute concentration
gradients controlling the velocity of the moving front.
4. Results and Discussion
4.1. Rheological Measurements
The concentration of gellan gum (GG) used for the preparation of the beads was carefully
optimized on the basis of the rheological properties of its solutions. Specifically, GG solutions at
1.0, 1.5 and 2.0% w/w were prepared at 80 ◦C and, after complete solubilization, cooled to 40 ◦C.
The flow curves obtained at this temperature for the three solutions of GG are reported in Figure 4A.
The viscosity of the system increases by increasing the polymer concentration and the dependence of
the viscosity on the shear rate is characteristic of a pseudo-plastic macromolecular system.
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Mechanical spectra were also recorded in the region of linear viscoelasticity and r ported in
Figure 4B. The polymeric solution at 1.0% w/w of GG showed a G’ smaller than G”, behaving as an
entanglement network (data not shown). By increasing the GG concentration, the polymeric solution
evolves towards a weak gel behavior, with G’ bigger than G” and slightly dependent on the frequency.
During the cooling, GG undergoes a series of structural changes in aqueous solution from random
coiled chains to double helices, which then aggregate together thus forming a three-dimensional
network. This behavior is well known as the gelation mechanism of gellan gum alone or in the presence
of cations has been extensively investigated by different techniques, such as rheological, DSC and light
scattering measurements and reviewed in [31].
Preliminary experiments were carried out in order to verify if the three solutions could flow
through a syringe needle. GG solutions were loaded into the syringe at 40 ◦C. This temperature value
was chosen in order to avoid any possible thermal damage when drugs are loaded inside the systems.
GG concentrations greater than 1.5% w/w resulted in a highly viscous solution that caused clogging of
the syringe needle, so that only the solutions at 1.0% and 1.5% w/w GG were used to prepare the beads.
The morphology of the forming beads by ionotropic gelation strongly depends on the amount
of gellan gum in the initial mixture [32– ]. l r t ly er content, the more deformed and
irregular the beads, due to the ma rix-forming function of gellan. Moreover, if the GG concentration is
too low, the beads l st ir spherical shape during the drying process, as al eady observe in [34].
In fact, both polymer and cross-linker co centratio s have major effects on morphology as well as
on other properties of the resulting beads, as reviewed in [10], because both concentrations affect the
kinetic of the crosslinking process.
Our preli inary tests sho ed that the polymer concentration represents the main factor controlling
the morphology of the beads. For GG concentrations lower than 1.5% w/w, the solution was unable to
produce stable spherical beads, most likely because the low viscosity of the solution does not allow
to keep the spherical shape of the drops when in contact with the cross-linking solution. For this
reason, concentrations of GG below 1% w/w were not further investigated and the GG concentration of
1.5% w/w was chosen (see Section 4.2).
The effect of clay on the rheological properties of GG was also investigated. To this end, 1.0% w/w
of laponite was added to the GG solution at 1.5% w/w. Flow curves and mechanical spectra performed
on the polymeric solution containing the clay are shown in Figure 5A,B.
The presence of laponite induces a small decrease of viscosity of the polymeric solution as well as
of the G’ value, most likely because the clay interacts with the gellan chains, thus partially destroying
the double helix structure and causing the formation of a weaker gel. Indeed, the mechanical spectrum
of the GG solution shows a weak gel behavior with the modulus G’ higher than G” in the entire range
of frequencies analyzed. On the contrary, the GG solution with laponite shows an intersection point of
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the G’ and the G” curves at frequency of about 1 Hz, thus behaving as a solution (with G” > G’) for
higher values of the applied frequency.
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4.2. Beads Preparation
Based on the rheological properties of its solutions, different GG beads were prepared dropping
GG solution at 1% w/w and 1.5% w/w into CaCl2 solutions at different concentrations in order to
evaluate the effect of the cross-linking agent on the properties of the resulting beads.
The crosslinking process involves calcium ions and carboxylic groups of D-glucuronic acid of GG.
More specifically, every calcium ion can electrostatically interact with two carboxylic groups; therefore,
it interacts with two d-glucuronic acids of two different repetitive units of the polymer.
The crosslinking concentration always exceeded the concentration of the polymer as molar ratios
GG:Ca2+ of 1:5, 1:7.5, 1:10 and 1:15 mol:mol were investigated. Regular and spherical beads were
obtained with GG concentration 1.5% w/w for 1:5 and 1:10 G :Ca2+ molar ratios, corresponding to
CaCl2 concentrations of 0.3% w/w and 0.6% w/w, respectively. Concentrations of CaCl2 < 0.3% w/w
hav not produced stable and spherical beads. GG solution 1.0% w/w gave irregular beads even for
higher GG:Ca2+ molar ratios 1:7 and 1:15. Based on these results, concentrations of GG below 1% w/w
were not further investigated and the GG concentration of 1.5% w/ with CaCl2 concentrations of
0.3% w/w and 0.6% w/w were adopted because these conc trations did ot caus clogging of the
syringe needle and produced regul r and sph rical beads. Further formulations were prepared by
adding laponite to GG solution before beads formation. In this case, the beads were formed using
the GG solution 1.5% w/w with laponite 1% w/w and with the lower concentration 0.3% w/w of CaCl2,
which was ch sen by considering that the clay is able to act as cross-linker itself, thus contributing to
the polymeric network formation.
The beads were recovered by filtration a d characterized immediately after preparation in their
fresh form and aft r the freeze- rying pro ess. Specifically, they were observed at the optical microscope
and their diameters measure and reported in Table 1.
Table 1. Diameter values of different bead formulations before and after freeze-drying.
Beads Formulation Beads Diameter(mm ± SD)
Freeze-Dried Beads Diameter
(mm ± SD)
GG/Ca 0.3% 2.41 ± 0.06 1.63 ± 0.03
GG/Ca 0.6% 2.44 ± 0.07 1.56 ± 0.09
GG/LAPO/Ca 0.3% 2.79 ± 0.11 2.06 ± 0.08
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Different formulations lead to beads with different dimensions: the cross-linker concentration
does not influence significantly the particle diameter, whereas the presence of laponite leads to an
increase of the particle diameter. For all formulations, the bead population appear homogeneous
and with spherical shape (see Figure 6A) characterized by an aspect ratio of about 1.02. The beads
containing laponite (Figure 6D) have a smoother and regular surface with respect to the other ones
(Figure 6B,C which differ for the CaCl2, concentration), most likely because the clay, acting as filler,
increases the particle surface compactness.
Particle density after freeze-drying ρb is extremely low and comparable for all formulations.
Specifically, ρb = 0.109 ± 0.02 g/cm3 for GG/Ca 0.3% and ρb = 0.0926 ± 0.02 g/cm3 for GG/LAPO/Ca 0.3%.
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network chains to stay closer to each other, resulting in a smaller swelling degree in acid medium. 
The beads in SIF exhibit a larger swelling degree as the carboxylic groups are deprotonated, resulting 
in a repulsion effect between network chains. 
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4.3. Swelling Experiments
A crucial property of the polymeric beads is the ability to s ell in aqueous environments. The
results of swelling experiments are reporte in able 2 in ter s of the swelling degree at equilibrium
Seq (after 24 h).
Table 2. Swelling degre at equilibri eq ( easured after 24 h) and effective solvent diffusion
coefficient Dssg of different bea f s i Si ulated Gastric Fluid (SGF; HCl 0.1 M) and
Simulated Intestinal Fluid (SIF; phosphate b ff . , .4).
Beads Formulation Seq in SGF Seq in SIF Dssg in SGF [m2/s] Dssg in SIF [m2/s]
GG/Ca 0.3% 9.08 ± 0.3 45.80 ± 0.9 (8.8 ± 0.3) × 10−10 (1.5 ± 0.1) × 10−9
GG/Ca 0.6% 8.97 ± 0.2 25.44 ± 0.6 - -
GG/LAPO/Ca 0.3% 9.14 ± 0.3 20.60 ± 0.3 (6.5 ± 0.3) × 10−10 (1.1 ± 0.1) × 10−9
In general, the swelling degree decreases in both swelling media as the amount of cross-linker is
increased. The significant differences observed in swelling degree values in SGF and SIF are related
to the nature of GG. The carboxylic groups of GG exist in a protonated form in HCl. This allows the
network chains to stay closer to each other, resulting in a smaller swelling degree in acid medium.
The beads in SIF exhibit a larger s elling degree as the carboxylic groups are deprotonated, resulting
in a repulsion effect between network chains.
The presence of laponite causes a remarkable decrease of the equilibrium value Seq as already
observed in [17] dealing with beads made of pH sensitive laponite/alginate/CaCl2 hybrid hydrogel.
In agreement with experimental findings reported in [17], the effect of clay is not only to decrease the
equilibrium swelling degree but also to reduce the solvent diffusion coefficient Dssg in both media,
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as reported in Table 2. In agreement with swelling degrees at equilibrium, Table 2 also shows that Dssg
is larger for SIF than for SGF for particles with and without clay. The values of Dssg reported in Table 2
for different beads and different media are obtained from the best-fit of experimental data for the time
evolution of the swelling degree S(t) with the swelling model developed in Section 3.1.
Figure 7 shows the comparison between experimental data for S(t) and the swelling model
predictions where:
(1) the parameter β has been set to the value β = 2 in order to account for the large porosity/small
density of beads;
(2) the solvent volume fraction (SGF or SIF) at equilibrium ϕeq is directly estimated from the
equilibrium swelling degree Seq as
ϕeq =
xeq/ρs(
1− xeq
)
/ρb + xeq/ρs
, xeq = 1− 1/
(
1+ Seq
)
, (17)
where xeq is the solvent weight fraction at equilibrium and ρb is the dry particle density;
(3) ϕG has been set to ϕG = 0.1ϕeq, given the ease of beads re-hydration after freeze-drying.
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It is important to point out that, even if the increase in the particle diameter is not so large, it is 
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based mainly on the analysis of release curves at short time scales and is strongly influenced by the 
variation of the diffusional lengths. Adopting a fixed boundary model leads to an error of the drug 
Figure 7. Comparison betwe n the swelling model predictions (continuous lines) and experimental
data (points) for the temporal evolution of the swelling degre S(t) for two different bead formulations
(GG/Ca 0.3% and GG/LAPO/Ca 0.3%) and two different swelling media (SGF and SIF). The best fit
values for the solvent diffusion coefficient in the swollen gel Dssg are reported in Table 2.
Figure 8 shows the time volution of particle diameter as predicted by the swelling model and the
satisfactory ag eement with experimental data for particle diameter at equilibrium. It can be observed
that dry particles, given the high porosity and the sm ll density, re able to absor a large amount of
solvent, e.g., about 50 times their initial weight for GG/Ca 0.3% formulation in SIF, while the diameter
at quilibrium at the most doubles its initial value. The swelling model, being able to account for
the high pa ticl porosity, furnishes a reliable forecasting estimate of the equilibrium diameter and
of the time-scale for reaching quilibrium conditions, approximately 15–20 in for all the different
formulations in the two media.
It is important to point out that, even if the increase in the particle diameter is not so large, it is
however extremely important to adopt a release model that takes into ac ount the swelling and the
variation of the diameter of the particle over time, as the estimate of the effective drug diffusivity is
based mainly on the analysis of release curves at short time scales and is strongly influenced by the
variation of the diffusional lengths. Adopting a fixed boundary model leads to an er or of the drug
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diffusion coefficient at least of a factor (deq/d0)2 where deq and d0 are the equilibrium and initial particle
diameter, respectively.
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4.4. Entrapment Efficiency
Two model drugs of different molecular weights and dimensions were loaded into the beads,
namely theophylline (MW 180, van der Waals radius 3.7 Å, aqueous solubility 8.3 mg/mL; pKa
8.6 [35]) and vitamin B12 (MW 1356, van der Waals radius 21 Å, aqueous solubility 10–33 mg/mL,
pKa = 3.28 [36]) in order to verify the possible use of freeze-dried beads for the oral administration
of drugs.
Table 3 reports the entrapment efficiency of the two drug molecules into two different bead
formulations, GG/Ca 0.3% w/w and GG/LAPO/Ca 0.3% w/w. It is evident that the entrapment efficiency
is influenced by both the bead structure and the steric hindrance of the loaded molecule. Indeed,
theophylline, smaller than vitamin B12, is less retained by both bead formulations, whereas the presence
of laponite increases the entrapment efficiency of both drug molecules. This will reflect in drug-release
data analyzed in the next section. The fact that the presence of laponite increases the drug entrapment
efficiency has been already observed in [17] for methylene blue loaded laponite/alginate beads.
Table 3. Entrapment efficiency of two model drug molecules, theophylline and vitamin B12.
Beads Drug Molecule Entrapment Efficiency (%)
GG/Ca 0.3% Vitamin B12 53.62
GG/LAPO/Ca 0.3% Vitamin B12 61.26
GG/Ca 0.3% Theophylline 20.26
GG/LAPO/Ca 0.3% Theophylline 36.49
4.5. Release Data Analysis
4.5.1. Theophylline Release
We preliminary analyzed release data of theophylline from beads GG/Ca 0.3% w/w without
laponite in both media SGF and SIF. Release data are shown in Figure 9A,B in terms of the withdrawal
concentration Cres (twi), from now on referred to as differential release curve, and of the integral release
curve Mt/M∞.
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It can be observed that integral release curves exhibit typical Fickian behavior in both media and
any type of physical/chemical drug/polymer interaction can be excluded. Continuous lines represent
theoretical predictions obtained with the no-drug-polymer interaction model Equations (11)–(13)
developed in Section 3.2, numerically solved together with the swelling model Equations (6)–(9) for
which the parameter values, specifically Dssg and β, reported in Section 4.3, were estimated from
independent swelling measurements. The only best-fit parameter entering the drug release model is
the theophylline diffusivity in the swollen gel Ddsg, whose values are reported in Table 4 for both media.
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Table 4. Theophylline diffusivity in the swollen gel Ddsg for two different bead formulations (with and 
without laponite) and two different media SGF and SIF. 
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Figure 9. Differential (A) and integral release curves (B) for theophylline (TPH) from beads GG/Ca
0.3% w/w without laponite in SGF and SIF. Continuous lines represent model predictions Equations
(11)–(13). Estimated values of the TPH effective diffusivity Ddsg are reported in Table 4.
It is important to point out that, for an accurate estimate of Ddsg, the model best-fit must be
performed on differential experimental data of Cres (twi), instead of on the integral release curve Mt/M∞,
Cres (twi) data being more sensitive to Ddsg both in the initial phase of rapid concentration rise and in
the subsequent phase where the effect of withdrawals become significant and not negligible.
The finite volume Vres of the reservoir is explicitly taken into account in model formulation, as well
as the withdrawals, as can be observed from the sawtooth behavior of the differential release model
curve. In fact, smaller values of Vres, which do not guarantee the perfect sink condition, are to be
preferred as they ensure better mixing and greater uniformity of drug concentration in the reservoir.
Imperfect mixing is difficult to model and leads to a withdrawal drug concentration that may depend
on the withdrawal point. On the contrary, the non-negligible drug concentration in the perfectly
mixed reservoir (Cres > 0, no sink condition) can be easily modeled by means of a macroscopic balance
equation (see Equation (13)). The only require ent is that Vres must be greater than a minimum
value that guarantees that the maximum value attained by Cres(t) during the release experiment is
significantly lower than drug solubility in the release medium. This condition is always fulfilled in our
release experiments for both drugs and for all Vres analyzed.
Table 4. Theophylline diffusivity in the swollen gel Ddsg for two different bead formulations (with and
without laponite) and two different media SGF and SIF.
Beads Ddsg in SGF [m2/s] Ddsg in SIF [m2/ ]
GG/Ca 0.3% (4.26 ± 0.15) × 10−10 (2.62 ± 0.2) × 10−10
GG/LAPO/Ca 0.3% (2.73 ± 0.3) × 10−11 (1.43 ± 0.1) × 10−10
From integral release data shown in Figure 9B and diffusivity values reported in Table 4 it can
be readily observed that theophylline release from beads without clay, despite the larger degree of
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swelling in SIF than in SGF, is faster in SGF than in SIF. Theophylline effective diffusivity in the bead
swollen in SGF is about half the value in aqueous solution DTPH ≈ 8.2 × 10−10 m2/s, while it reduces to
a quarter of DTPH in the bead swollen in SIF. This can be explained in terms of the screening effect of
the COO– groups of GG by the ions in SGF solution, thus reducing the possible interaction between
theophylline and the charged polymer. A similar phenomenon has been observed by Coviello et al.
(1999) [37] for theophylline in sclerox, a polycarboxylated derivative of scleroglucan.
In [37] the authors reported that theophylline diffusion rate in sclerox, without crosslinker, was
increased in acid medium with respect to that in SIF, while a diffusion rate lower in acid medium than
in SIF was observed in sclerox in the presence of alkane dihalides as crosslinker. We observed the
same inversion phenomenon from release data of theophylline in GG beads with and without laponite,
acting as a crosslinker as supported by swelling data.
Figure 10A,B shows release data for theophylline from beads GG/LAPO/Ca 0.3% in SGF and SIF
and the comparison with model predictions with the corresponding effective diffusion coefficients Ddsg
reported in Table 4. In the presence of clay, theophylline diffusivity reduces by an order of magnitude
with respect to DTPH in both media, but it is significantly smaller in SGF than in SIF. In this case,
diffusivity values are in agreement with swelling data, Seq being significantly larger in SIF than in SGF
for GG beads including laponite (see Table 2). Therefore, the screening effect of the COO– groups of
GG by the ions in SGF solution, although still present, is balanced and overcome by the reduced mesh
size of the network, this last observation being supported by swelling data in Figure 7 and Table 2.
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Equations (11–13). Estimated values of the TPH diffusivity Ddsg are reported in Table 4. 
This observation is in agreement with experimental findings reported in [17] focusing on drug 
release (methylene blue) from beads made of pH sensitive laponite/alginate/CaCl2 hybrid hydrogel. 
These authors observed that the presence of laponite induced a significant slowing down of the 
release kinetic of hydrophilic drugs especially in acid medium. 
Reliability and accuracy of the experimental release curves above presented, as well the 
predictive ability of the release model proposed, are confirmed by the analysis of gastrointestinal 
release data, i.e., release data obtained by immersing the beads sequentially first in SGF for 120 min 
and subsequently in SIF for 120 min, thus simulating the gastrointestinal release in-vitro. 
Figure 10. Differential (A) and integral release curves (B) for theophylline (TPH) from beads
GG/LAPO/Ca 0.3% with laponite in SGF and SIF. Continuous lines represent model predictions
from Equations (11)–(13). Estimated values of the TPH diffusivity Ddsg are reported in Table 4.
This observation is in agreement with experimental findings reported in [17] focusing on drug
release (methylene blue) from beads made of pH sensitive laponite/alginate/CaCl2 hybrid hydrogel.
These authors observed that the presence of laponite induced a significant slowing down of the release
kinetic of hydrophilic drugs especially in acid medium.
Reliability and accuracy of the x erimental lease curves above pre ented, as well the predictive
abi ity of the release mo el propos , are confirmed by the analysis of gastroi testinal release data, i.e.,
release data obtained by immersi g the beads sequentially first i SGF for 120 min and subsequently
in SIF for 120 min, thus simulating the gastrointestinal release in-vitro.
Figure 11A–D shows the differential (A and C) and the integral (B and D) gastrointestinal
release curves of theophylline from beads GG/Ca 0.3% (A,B) without laponite and GG/LAPO/Ca 0.3%
with laponite (C,D). Continuous lines show the excellent agreement between experimental data and
theoretical curves obtained from the release model used in a fully predictive way, by making use of the
TPH diffusivity values Ddsg previously estimated and reported in Table 4.
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It can be observed that TPH release from beads without laponite is so fast in SGF that 95% of
the drug is released in acid medium in the first 120 min. On the contrary, the presence of laponite
significantly slows down TPH release in SGF, so that about 70% of drug is released in acid medium,
and the remaining 30% is slowly released in the intestinal tract. We conclude that bead formulation
including laponite represents a release medium capable of supporting the controlled release of a small
non-interacting drug as theophylline.
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Figure 11. Gastrointestinal differential (A,C) and integral release curves (B,D) for theophylline (TPH)
from beads GG/Ca 0.3% without laponite (A,B) and GG/LAPO/Ca 0.3% with laponite (C,D), p < 0.001.
Continuous lines represent model predictions from Equations (11)–(13) with TPH diffusivity Ddsg
reported in Table 4.
4.5.2. Vitamin B12 Release
We preliminary analyzed release data of vitamin B12 from beads GG/Ca 0.3% without laponite in
both media SGF and SIF. Differential and integral release data are shown in Figure 12A,B respectively.
Additionally, for vitamin B12, as for theophylline, integral release curves from bead formulation
without laponite exhibit typical Fickian behavior in both media. Continuous lines represent theoretical
predictions obtained with the no-drug-polymer interaction model in Equations (11)–(13) developed in
Section 3.2. B12 diffusivity values Ddsg in SGF and SIF are reported in Table 5.
It can be observed that B12 diffusivities in both media are: (1) smaller than the corresponding ones
for theophylline, as expected given the larger dimension of vitamin B12 and the bigger steric hindrance;
(2) comparable in SIF and SGF, despite the larger differences between swelling degrees, as the screening
effect in acid medium compensates the reduced mesh size of the network. Moreover, vitamin B12
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diffusivity in SIF is in quantitative agreement with diffusivity value DB12 ≈ 2.1 × 10−10 m2/s reported
in [38] for vitamin B12 in scleroglucan/borax hydrogel swollen in distilled water (pH 5.4).
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Like for theophylline, vitamin B12 release from beads without clay in SGF is fast enough so that 
the gastrointestinal release data shown in Figure 13 present an almost complete drug release in the 
gastric tract (98% of drug released after 120 min in SGF) and almost no drug is left to be released in 
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Figure 12. Differential (A) and integral release curves (B) for vitamin B12 from beads GG/Ca 0.3%
without laponite in SGF and SIF. Continuous lines represent model predictions from Equations (11)–(13).
Estimated values of the B12 diffusivity Ddsg are reported in Table 5.
Table 5. Vitamin B12 diffusivity in the s ll el Ddsg and transfer rate coefficient kbgsg f r two
different bead formulations (with and without laponite) and two different media SGF and SIF.
Beads Ddsg in SGF [m2/s] Ddsg in SIF [m2/s] kbgsg in SGF [1/s] kbgsg in SIF [1/s]
GG/Ca 0.3% (1.53 ± 0.15) × 0−10 (1.85 ± 0.15) 10−10 - -
GG/LAPO/Ca 0.3% (2.87 ± 0.1) × 10−11 (5.33 ± 0.1) × 10−11 2.35 × 10−4 4.12 × 10−3
Like for theophylline, vitamin B12 release from beads without clay in SGF is fast enough so that
the gastrointestinal release data shown in Figure 13 present an almost complete drug release in the
gastric tract (98% of drug released after 120 min in SGF) and almost no drug is left to be released in the
intestinal tract. Therefore, the bead formulation without laponite is not suitable for controlled release
of a medium/large non-interacting drug molecule.Pharmaceutics 2019, 11, x 19 of 22 
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A completely different scenario opens up when laponite is included in bead formulation and
vitamin B12 release data are analyzed. Figure 14 shows integral release data of vitamin B12 from beads
GG/LAPO/Ca 0.3% including laponite in SIF and SGF. It can be readily observed that drug release in
SGF exhibits non-Fickian behavior Mt/M∞ ≈ tn with an exponent n = 1.2 much bigger than 12 .
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This is a clear symptom that an interaction occurs between vitamin B12 and the polymer/clay
complex. This interaction is strongly weakened by the enlarged mesh size of the network induced by
matrix swelling in SIF while it is stronger and sustained by the reduced swelling in SGF.
For this reason, we adopted the two-phase model developed in Section 3.3 describing
drug/clay-polymer interaction in terms of a linear transfer rate from a bounded phase, in which
drug molecules are initially entrapped, to a gel phase in which drug molecules are free to diffuse
and exit the swelling bead. Figure 14 shows good agreement between integral release data and the
two-phase model predictions Equations (13)–(16). Best-fit values of vitamin B12 diffusivity Ddsg and
transfer rate constant kbgsg in SIF and SGF are reported in Table 5.
The transfer rate coefficient kbgsg for vitamin B12 in SGF is one order of magnitude smaller than
that in SIF. The diffusivity Ddsg is smaller in SGF than in SIF.
By analyzing these findings in terms of the Thiele modulus Φ2 (introduced in Section 3.3), we
observe that Φ2 for vitamin B12 in GG/LAPO/Ca 0.3% attains the following values: Φ2 ≈ 80 in SIF
and Φ2 ≈ 9 in SGF. Therefore, Φ2 in SGF is one order of magnitude smaller than Φ2 in SIF. This
quantitatively explains why drug-polymer/clay complex interaction leads to a strong non-Fickian
behavior in SGF, characterized by a slower release at short time scale because the diffusion time-scale
is comparable to the transfer time scale, while a Fickian behavior is observed for vitamin B12 in SIF
because diffusion is definitely the rate controlling step.
Diffusivity values Ddsg for vitamin B12 are actually much lower in the beads with laponite in
both media, and this, together with drug interaction with the polymer/clay complex, reflects in the
gastrointestinal release curve shown in Figure 13 together with the corresponding vitamin B12 release
curve from beads without laponite. The continuous blue curve represents the two-phase model
prediction, from Equations (13)–(16), of the gastrointestinal release without any adjustable parameters.
In the presence of laponite, only 60% of the loaded vitamin B12 is released in the gastric tract (first
120 min), and also the remaining 40% is slowly released in the intestinal tract, as the complete release
requires about 280 min in SIF medium. Therefore, the bead formulation including laponite is suitable
for sustained release of a medium/large interacting drug molecule.
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5. Conclusions
Gellan gum, a natural polysaccharide, was employed together with calcium chloride, selected as
cross-linker, in order to prepare beads using the ionotropic gelation method. Laponite, a synthetic clay,
was also included in the formulations. Stable and spherical beads (aspect ratio ≈ 1.02) were obtained
from GG solutions (GG 0.15 % w/w) and GG/laponite solutions (GG 0.15% w/w, laponite 0.1% w/w)
with CaCl2 0.3% w/w. Gellan gum beads including laponite have shown a smoother and regular
surface and a larger diameter, namely d0 ≈ 2.8 mm and d0 ≈ 2.1 mm before and after freeze-drying,
respectively. The ability to swell in different media mimicking biological fluids, namely SGF and SIF,
was investigated. The bead swelling degree at equilibrium was lower in SGF than in SIF and further
reduced in the presence of laponite.
Two model drugs, theophylline and vitamin B12, having different molecular weight and steric
hindrance, were loaded into different bead formulations. The presence of laponite in the bead
formulation increased the drug entrapment efficiency for both model drugs. Sustained release of both
model drugs was obtained from beads including laponite, as a small fraction of the incorporated drugs
was released in the gastric medium. This suggests that laponite may be an effective additive in the
development of GG beads for sustained release of drugs. Better results in terms of sustained release
were obtained for vitamin B12 as it exhibited a significant interaction with the clay/polymer composites
in SGF. In the absence of laponite, both drugs were almost completely released in the first two hours of
residence in SGF.
The swelling model with “diffuse interface” and the corresponding drug release models developed
for polymer/clay beads no-interacting and interacting drugs have proved to be able to correctly describe
all the phenomena experimentally observed and to furnish reliable drug diffusivity values in agreement
with literature data for the same drugs in similar physical hydrogels.
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